Cwm LLC Purchases 16,429 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Cwm LLC lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 203.4% in the second quarter, Holdings Channel.com reports. The fund owned 24,507 shares of the medical equipment provider’s stock after acquiring an additional 16,429 shares during the quarter. Cwm LLC’s holdings in Zimmer Biomet were worth $2,235,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ZBH. Brighton Jones LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $204,000. GAMMA Investing LLC raised its position in shares of Zimmer Biomet by 52.4% during the first quarter. GAMMA Investing LLC now owns 3,502 shares of the medical equipment provider’s stock worth $396,000 after acquiring an additional 1,204 shares during the last quarter. Janney Montgomery Scott LLC raised its position in shares of Zimmer Biomet by 0.5% during the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock worth $2,903,000 after acquiring an additional 118 shares during the last quarter. QRG Capital Management Inc. raised its position in shares of Zimmer Biomet by 13.9% during the first quarter. QRG Capital Management Inc. now owns 6,775 shares of the medical equipment provider’s stock worth $767,000 after acquiring an additional 827 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC raised its position in shares of Zimmer Biomet by 20.0% during the first quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider’s stock worth $295,000 after acquiring an additional 435 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Trading Up 2.1%

Shares of Zimmer Biomet stock opened at $102.00 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $114.72. The stock has a 50 day moving average price of $101.74 and a two-hundred day moving average price of $97.78. The stock has a market capitalization of $20.21 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 2.35 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same quarter last year, the firm posted $2.01 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. BTIG Research raised their price objective on Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Roth Capital reaffirmed a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Evercore ISI decreased their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research note on Tuesday, October 7th. Finally, Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $111.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.